Stock itci.
As of Jun 30, 2023, ITCI had cash, cash equivalents, restricted cash and investment securities of $514.6 million compared with $540.5 million as of Mar 31, 2023. 2023 Guidance Updated
In a report released on April 6, Brian Abrahams from RBC Capital maintained a Buy rating on Intra-Cellular Therapies ( ITCI – Research Report ), with a price target of $72.00. The company’s ...Referenced Symbols. Shares of Intra-Cellular Therapies Inc. ITCI, +3.26% jumped about 15% in premarket trading on Tuesday after the company said its experimental treatment for major depressive ... Intra-Cellular Therapies (ITCI) shares soared 16.4% in the last trading session to close at $55.73. The move was backed by solid volume with far more shares changing hands than in a normal session.The company increased its Caplyta net product sales in the range of $445-$465 million (previously $430-$455 million) for the full-year 2023. Intra-Cellular, however, maintained its full-year 2023 ...
GuruFocus Research November 2, 2023 at 10:17 AM · 2 min read Intra-Cellular Therapies Inc ( NASDAQ:ITCI) reported Q3 2023 total revenues of $126.2 …
Intra-Cellular Therapies Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ITCI updated stock price target summary.Stock analysis for Intra-Cellular Therapies Inc (ITCI:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
04:20 PM ET 03/28/2023. Intra-Cellular Therapies ( ITCI) said Tuesday that its depression treatment succeeded in a key study, and ITCI stock broke definitively above its 200-day line for the first ...Covering ITCI for Jefferies, analyst Andrew Tsai writes: “In 2022, we think ITCI stock could break all-time highs despite a challenging tape, as Caplyta scripts are accelerating earlier (and ...NEW YORK, April 09, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced plans to present analyses from its open-label safety switching study (Study 303) assessing the effects of long-term …Intra-Cellular Therapies Inc. stock grades by Barron's. View ITCI fundamental and sentiment analysis powered by MarketGrader.
In terms of how INTRA-CELLULAR THERAPIES INC fares relative to Pharmaceutical Products stocks, note that its average analyst price target is higher than 3826.61% of that group. ITCI has a greater number of analysts covering the stock than 3418.44% of stocks in the mid market cap category.
Current Price $59.26 Daily Change (1.2%) $0.73 Day's Range $58.34 - $60.25 Previous Close $59.26 Open $59.71 Beta 0.95 Volume 666,350 Average Volume 831,756 Sector …
The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $78.67. ITCI has been the topic of a number of research analyst reports. Needham & Company LLC lifted their target price on Intra-Cellular Therapies from $71.00 to $72.00 and gave the stock a “buy” rating in a report on Friday ...Our Mission. Our mission is to deliver innovative treatments to improve the lives of individuals with neuropsychiatric, neurologic, and other disorders to reduce the burden on patients and their caregivers.Shares of Intra-Cellular Therapies (ITCI) have gained 7.7% over the past four weeks to close the last trading session at $56.01, but there could still be a solid upside left in the stock if short ...ITCI is a biopharmaceutical company that develops novel drugs for treating neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system. On August 22, 2022, The Goldman Sachs Group Inc. ( GS ) downgraded ITCI from a “buy” rating to a “neutral” rating.Intra-Cellular Therapies Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ITCI updated stock price target summary.
ITCI stock rallied 2.2% Friday. Inspire Medical Systems ( INSP ) posted a weekly gain despite three losing days, gaining 3.8% Friday. INSP shares formed a handle and flirted with the 277.28 buy ...ITCI The Nasdaq Global ... On January 10, 2020, the Company completed a public offering of common stock in which the Company sold ...Nov 27, 2022 · Headquartered in Chelmsford, Massachusetts, Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is a sample exploration and management solutions provider for the life science market. On November 23, 2022 ... Zacks Investment Research is releasing its prediction for ITCI based on the 1-3 month trading system that more than doubles the S&P 500. Click here - the ITCI analysis is free ». Price. 2021 ...TipRanks | Stock Market Research, News and Analyst Forecasts ... March 31, 2023 at 11:30 AM · 4 min read. It has been about a month since the last earnings report for Intra-Cellular Therapies (ITCI). Shares have added about 20.5% in that time frame ...A high-level overview of Intra-Cellular Therapies, Inc. (ITCI) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and …
Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up Zacks - Wed Mar 29, 11:27AM CDT . Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. Stock surges 16% following the news.When it comes to purchasing a new vehicle, finding the perfect car that meets all your requirements can be a daunting task. If you have your heart set on a Genesis GV70, you’ll want to ensure that you find the best one available in stock.
0001193125-20-214163.txt : 20200810 0001193125-20-214163.hdr.sgml : 20200810 20200810081722 ACCESSION NUMBER: 0001193125-20-214163 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENTStock Price Forecast. The 13 analysts offering 12-month price forecasts for Intra-Cellular Therapies Inc have a median target of 76.00, with a high estimate of 101.00 and a low estimate of 58.00 ...According to Accountingbase.com, common stock is neither an asset nor a liability; it is considered equity. Equity is basically considered to mathematically be the difference between the total assets and total liabilities of a company.The average price recommended by analysts for Intra-Cellular Therapies Inc (ITCI) is $77.54, which is $16.26 above the current market price. The public float for ITCI is 93.65M and currently, short sellers hold a 3.65% of that float. On December 01, 2023, ITCI’s average trading volume was 845.52K shares. Top 5 EV Tech Stocks to Buy for 2023.In the past 90 days, the Zacks Consensus Estimate for Aptinyx’s 2023 loss per share has narrowed from 77 cents to 47 cents. In the past year, shares of Aptinyx have fallen by 86.8%. APTX beat ...The average twelve-month price prediction for Intra-Cellular Therapies is $78.67 with a high price target of $101.00 and a low price target of $62.00. Learn more on ITCI's analyst rating history. Do Wall Street analysts like Intra-Cellular Therapies more than its competitors?
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
Our Mission. Our mission is to deliver innovative treatments to improve the lives of individuals with neuropsychiatric, neurologic, and other disorders to reduce the burden on patients and their caregivers.50.24%. Get the latest Intra-Cellular Therapies Inc (ITCI) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...Mar 28, 2023 · 04:20 PM ET 03/28/2023. Intra-Cellular Therapies ( ITCI) said Tuesday that its depression treatment succeeded in a key study, and ITCI stock broke definitively above its 200-day line for the first ... Covering ITCI for Jefferies, analyst Andrew Tsai writes: “In 2022, we think ITCI stock could break all-time highs despite a challenging tape, as Caplyta scripts are accelerating earlier (and ...The stock of Intra-Cellular Therapies Inc (ITCI) has gone up by 5.10% for the week, with a -1.20% drop in the past month and a -13.62% drop in the past quarter. The volatility ratio for the week is 5.20%, and the volatility levels for the past 30 days are 3.88% for ITCI. The simple moving average foNov 28, 2023 · ITCI Stock Overview. Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up Zacks - Wed Mar 29, 11:27AM CDT . Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. Stock surges 16% following the news.Find the latest Intra-Cellular Therapies, Inc. (ITCI) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Nov 28, 2023 · Zacks Investment Research is releasing its prediction for ITCI based on the 1-3 month trading system that more than doubles the S&P 500. Click here - the ITCI analysis is free ». Price. 2021 ...
Intra-Cellular Therapies Inc. research and ratings by Barron's. View ITCI revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.May 4, 2023 · Intra-Cellular (ITCI) delivered earnings and revenue surprises of 26.98% and 3.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? Intra-Cellular Therapies (ITCI) Stock Forecast, Price Targets and ...Instagram:https://instagram. wix com ltdarkf holdingswho owns rockstar energyforex broker mt4 View the basic ITCI option chain and compare options of Intra-Cellular Therapies, Inc. on Yahoo Finance.Even on an earnings season day when a clutch of companies notched earnings beats, Intra-Cellular Therapies' (ITCI 2.46%) first-quarter beat was notably impressive. Investors liked what they saw in ... parker share pricepng gaming The put/call ratio of ITCI is 0.42, ... VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 2,591K shares representing 2.70% ownership of the company. real time stock screener Intra-Cellular Therapies Inc. Common Stock (ITCI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.home / stock / itci / itci news. RSS . ITCI ITCI Quote ITCI Short ITCI News ITCI Articles ITCI Message Board. February, 24 2021 07:30 AM ... Feb. 24, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ...